Next Article in Journal
Polygenetic Variants Related to Osteoarthritis Risk and Their Interactions with Energy, Protein, Fat, and Alcohol Intake in Adults in a Large Cohort
Next Article in Special Issue
Factors Associated with Delirium in COVID-19 Patients and Their Outcome: A Single-Center Cohort Study
Previous Article in Journal
Metallic Component Preserving Algorithm Based on the Cerebral Computed Tomography Angiography in Aneurysm Surgery
Previous Article in Special Issue
Early Routine Biomarkers of SARS-CoV-2 Morbidity and Mortality: Outcomes from an Emergency Section
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 12
Issue 2
10.3390/diagnostics12020339
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Analysis of Early Biomarkers Associated with the Development of Critical Respiratory Failure in Coronavirus Disease 2019 (COVID-19)

by
Hiroyoshi Yamada
1,2,
Masaki Okamoto
1,2,*,
Yoji Nagasaki
3,
Suzuyo Yoshio
4,
Takashi Nouno
1,2,
Chiyo Yano
1,2,
Tomohiro Tanaka
1,2,
Fumi Watanabe
1,
Natsuko Shibata
1,
Yoko Arimizu
3,
Yukako Fukamachi
3,
Yoshiaki Zaizen
2,
Naoki Hamada
5,
Atsushi Kawaguchi
6,
Tomoaki Hoshino
2 and
Shigeki Morita
7
1
Department of Respirology and Clinical Research Center, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka 810-0065, Japan
2
Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Fukuoka 830-0011, Japan
3
Department of Infectious Disease, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka 810-0065, Japan
4
Shino-Test Corporation, 3-7-9 Kanda Surugadai, Chiyoda-ku, Tokyo 101-8410, Japan
5
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1 Maidashi Higashi-ku, Fukuoka 812-0054, Japan
6
Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan
7
Department of Cardiovascular Surgery, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka 810-0065, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2022, 12(2), 339; https://doi.org/10.3390/diagnostics12020339
Submission received: 26 December 2021 / Revised: 18 January 2022 / Accepted: 24 January 2022 / Published: 28 January 2022
(This article belongs to the Special Issue Biomarkers for Predicting Treatment Response and Guiding Therapy in COVID-19 Patients)
Browse Figure
Review Reports Versions Notes

Abstract

:
Certain biomarkers predict death due to acute respiratory distress syndrome in COVID-19 patients. We retrospectively analyzed biomarkers associated with time to mechanical ventilation for respiratory failure due to COVID-19 (time-to-mechanical ventilation) in 135 consecutive patients in our hospital. We analyzed biomarkers that were elevated immediately (at admission) and later (3 days after admission) using Cox proportional hazards regression analysis. Independent biomarkers of time-to-mechanical ventilation were high C-reactive protein (CRP), interleukin (IL)-6, and Krebs von den Lungen-6 (KL-6) concentrations at admission and elevated CRP, high-mobility group box-1 protein (HMGB-1), and d-dimer levels and low platelets 3 days after admission. Receiver operating characteristic analysis for detecting the association between independent biomarkers associated with time-to-event in multivariate analyses and the start of mechanical ventilation revealed that these biomarkers had area under the curve values higher than 0.700. The present study suggests that CRP was the only biomarker associated with time-to-mechanical ventilation both at admission and 3 days after admission. Moreover, IL-6 (an inflammatory cytokine), HMGB-1 (a late inflammatory mediator), and KL-6 (reflecting injury and/or remodeling of type II pneumocytes) were associated with outcomes in COVID-19 as reported previously. In conclusion, increased CRP, IL-6, KL-6, HMGB-1, and d-dimer levels and decreased platelet counts were associated with the start of mechanical ventilation due to COVID-19.

1. Introduction

The viral pneumonia outbreak that began in Wuhan, China, in December 2019 is presently ongoing, and the novel pathogen linked to this disease has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pneumonia caused by this virus, named coronavirus disease 2019 (COVID-19), has spread rapidly worldwide [1,2]. Although most COVID-19 patients have bilateral pneumonia without hypoxemia and asymptomatic or mild disease, some patients develop lethal respiratory failure.
The main cause of death in COVID-19 is the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) [1,2,3,4]. A systematic review and meta-analysis reported that the overall pooled mortality estimate among 10,815 ARDS cases in COVID-19 patients was 39% (95% confidence interval (CI): 23–56%) [4,5]. Mechanical ventilation (MV) is the key management strategy for ALI/ARDS in general infectious disease units (IDUs) or intensive care units (ICUs). Increased COVID-19 cases requiring MV can strain medical care resources in clinical practice. However, predicting the development of critical respiratory failure and stratifying patients early after admission may reduce this risk. Although some predictive blood biomarkers and risk factors, including older age, smoking, obesity, hypertension, diabetes mellitus, and coronary heart disease, have been reported, predictors of critical respiratory failure have not yet been established [3,4,5].
This study focused on determining biomarkers associated with the start of MV measured early after admission for COVID-19. An excessive immune response against SARS-CoV-2 induced by inflammatory cytokines and chemokines (i.e., cytokine storm) can contribute to the development of critical respiratory failure due to ALI/ARDS [6]. Previous studies have shown that serum levels of certain biomarkers were associated with disease severity and outcomes [7,8,9,10,11,12,13,14,15,16]. Moreover, studies using prediction models (ISARIC4C and COVID-GRAM) reported that the areas under the curve (AUC) for predicting the outcome of COVID-19 patients, including mortality and/or ICU admission, were 0.774 and 0.706, respectively [17,18].
In the present study, we attempted to clarify whether blood biomarkers measured early after admission are associated with the start of MV or death due to COVID-19.

2. Materials and Methods

2.1. Patients

This single-center retrospective study conducted a medical record review. The study subjects included 135 consecutive patients with COVID-19 who were admitted to our IDU from February 2020 to August 2020. The admission criterion to the IDU was a diagnosis of COVID-19 by SARS-CoV-2 real-time polymerase chain reaction using an oropharyngeal swab or sputum sample. Chest X-rays and computed tomography were performed in all patients to evaluate the presence of lower respiratory disease due to COVID-19. We classified the disease severity in patients with COVID-19 according to the National Institutes of Health criteria as follows [19]. Patients with COVID-19 with no symptoms consistent with COVID-19 were classified as the asymptomatic infection group. Patients with any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste, loss of smell) but without shortness of breath, dyspnea, or abnormal chest imaging were classified as the mild illness group. Patients who showed evidence of lower respiratory disease during clinical assessment or imaging and had >94% oxygen saturation (SpO2) in room air were classified as the moderate illness group. Patients with an SpO2 < 94% in room air were classified as the severe illness group, and patients with ARDS, septic shock, and/or multiple organ dysfunction were classified as the critical illness group. This classification of severity was determined by the condition at the time of admission.

2.2. Endpoints

The aim of the present study was to determine biomarkers associated with the start of MV in COVID-19 patients. Time-to-MV was defined as the time from admission to the start of MV to control respiratory failure due to COVID-19. The indication for MV was set similarly to that in clinical practice (i.e., respiratory failure that cannot be controlled by high-concentration oxygen therapy) [20].

2.3. Biomarker Analysis

We analyzed biomarker concentrations at admission and 3 days after admission to identify biomarkers elevated immediately and later after the onset of COVID-19. The serum concentrations of high-mobility group box-1 protein (HMGB-1), interleukin-6 (IL-6), IL-18 (an inflammasome-related cytokine) [21], and soluble CD163 (an M2-like macrophage-related biomarker shed from the cell surface by an inflammatory stimulus) were analyzed using residual serum [22]. The serum HMGB-1 level was measured using the HMGB1 ELISA Kit II (Shino-Test Co., Ltd., Sagamihara, Japan). The minimal detectable concentration (MDC) and coefficient of variation (CV) of this ELISA kit are 1 ng/mL and <10%, respectively. The serum level of IL-6 was measured by a chemiluminescent enzyme immunoassay using the human IL-6 measurement cartridge (MDC, 0.2 pg/mL; CV, 2.14–2.66%; Fujirebio Diagnostic Inc., Tokyo, Japan). The serum level of the inflammatory cytokine IL-18 was measured using a human IL-18 ELISA kit (MDC, 12.5 pg/mL; CV, 4.93–10.80%; Medical & Biological Laboratories Co., Ltd., Nagoya, Japan). The serum level of soluble CD163 was measured using a soluble CD163 ELISA kit (MDC, 0.177 ng/mL; CV, 3.4–3.8%; R&D Systems, Inc., Minneapolis, MN, USA). Other biomarkers including neutrophil, lymphocyte, and platelet counts and serum levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, Krebs von den Lungen-6 (KL-6), and d-dimer were measured as part of routine laboratory testing. Standard values of biomarkers were as follows: CRP, less than 0.20 mg/dL; KL-6, less than 500 IU/mL; LDH, less than 225 IU/L; IL-6, less than 6.6 pg/mL; soluble CD163, less than 472 pg/mL; neutrophil count, from 1800 to 7500/uL; lymphocyte count, 1000 to 4800/uL; platelet count range, 15.8 to 34.8 × 104/uL.

2.4. Statistical Analysis

Data were expressed as the median (25th–75th percentiles of the interquartile range). Differences between multiple groups were analyzed as appropriate using the Wilcoxon rank-sum test for two groups and the Kruskal–Wallis test for three groups, or Fisher’s exact test. In Cox proportional hazards regression analysis, we detected variables significantly (p < 0.05) associated with time-to-MV by univariate analyses. Next, all significant variables detected by univariate analyses were analyzed by multivariate analysis using the backward elimination method. The biomarker cut-off levels were defined as the optimal value with the highest Youden index on receiver operating characteristic (ROC) curves generated using logistic regression, as in our previous report [23]. The validity of the logistic regression analysis result was verified by the Hosmer and Lemeshow goodness of fit (GOF) test. The validity of ROC analysis was verified by implementing 5-repeated 10-fold cross-validation. A value of p < 0.05 was considered to represent statistical significance, and all statistical analyses were performed using the JMP 14.0 program (SAS Institute Japan, Tokyo, Japan).

3. Results

3.1. Patient Characteristics and Outcomes

The patients’ characteristics are presented in Table 1. The study cohort consisted of 135 patients (69 males; median age, 50.0 years) with COVID-19, including 42 with asymptomatic infections or mild illness (mild illness group), 66 with moderate illness (moderate illness group), 27 with severe illness (severe illness group), and none with critical illness (critical illness group), in accordance with the severity at admission. Among the 135 study cases, 22 (16.3%) had diabetes mellitus (DM), 33 (24.4%) had hypertension, and 9 (6.7%) had malignant disease. A comparison of clinical data by the severity at admission showed that more severe disease was associated with older age and male gender. The comparison of biomarker levels at admission showed that more severe disease was significantly associated with higher neutrophil counts, CRP, LDH, ferritin, IL-6, KL-6, and d-dimer and lower lymphocyte counts. The comparison of biomarker concentrations 3 days after admission showed that more severe disease was significantly associated with higher neutrophil counts, CRP, LDH, ferritin, IL-6, IL-18, KL-6, HMGB-1, soluble CD163, and d-dimer and lower lymphocyte counts. There was no difference regarding smoking status, platelet counts at admission and 3 days after admission, or the levels of HMGB-1 and soluble CD163 at admission among the three severity groups.
The patients’ clinical courses are presented in Table 2. Among all 135 patients, 5 (3.8%) patients died of COVID-19 in hospital 10, 17, 22, 44, and 76 days after admission. The median hospital stay period was 9.0 (6.0–15.0) days. Ten (7.4%) patients received MV, and one (0.74%) patient died of COVID-19 without receiving MV. Among the 10 (7.4%) patients receiving MV, 6 (4.4%) survived, and 4 (3.0%) died in hospital. One patient who refused MV because of advanced age received high-concentration oxygen therapy by a reservoir mask and maximum pharmacological therapy and died 17 days after admission.

3.2. Comparison of Biomarkers between Patients with and without MW

Table 3 shows the comparison of biomarker levels between cases with and without MV. Among the biomarkers at admission, patients with MV had significantly higher neutrophil counts, CRP, LDH, ferritin, and d-dimer and lower lymphocyte counts than those without MV. Similarly, patients with MV tended to have higher IL-6 and KL-6 levels and lower platelet counts than those without. IL-18, HMGB-1, and soluble CD163 levels were not significantly different between the two groups. Among the biomarkers 3 days after admission, patients with MV had significantly higher neutrophil counts, CRP, LDH, ferritin, IL-6, HMGB-1, and d-dimer and lower lymphocyte and platelet counts than those without MV or patients who survived. Soluble CD163 levels were not significantly different between the two groups. We could not measure KL-6 and IL-18 levels 3 days after admission owing to a lack of residual serum.

3.3. Cox Proportional Hazards Regression Analysis for Detecting Biomarkers Associated with Time-to-MV

The results of the univariate analysis are shown in Table 4. Among the biomarkers at admission, neutrophil counts and CRP, LDH, ferritin, IL-6, KL-6, and d-dimer levels were significantly associated with time-to-MV. Among the biomarkers 3 days after admission, neutrophil and platelet counts and CRP, LDH, ferritin, IL-6, HMGB-1, and d-dimer levels were significantly associated with time-to-MV.
The results of multivariate analyses using the backward elimination method are shown in Table 5. Among the biomarkers at admission, the independent biomarkers associated with time-to-MV were high levels of CRP (relative risk (RR), 33.1; 95% CI, 3.2–372.6; p = 0.0028), IL-6 (RR, 14.5; 95% CI, 0.67–142.7; p = 0.041), and KL-6 (RR, 64.7; 95% CI, 3.6–804.4; p = 0.0013). Among the biomarkers 3 days after admission, the independent biomarkers associated with time-to-MV were high levels of CRP (parameter estimate (PE) of RR, −0.33; PE of 95% CI, −0.96 to −0.044; p = 0.021), HMGB-1 (PE of RR, 0.22; PE of 95% CI, 0.054 to 0.46; p = 0.011), and d-dimer (PE of RR, 0.93; PE of 95% CI, 0.083 to 2.1; p = 0.00037) and low platelet counts (PE of RR, −0.37; PE of 95% CI, −0.72 to −0.14; p = 0.00060). The Hosmer–Lemeshow GOF test demonstrated the validity of the Cox proportional hazards regression analysis results of biomarkers at admission (p = 1.0) and 3 days after admission (p = 0.998) for predicting time-to-MV.

3.4. ROC Curve Analysis for Determining the Association between Biomarkers and the Start of MV

The results of ROC analyses for detecting the association between the independent biomarkers associated with time-to-event in the Cox proportional hazards regression analysis and the start of MV are shown in Table 6 and Figure 1. Among the biomarkers at admission, cut-off levels and AUCs were as follows: CRP, 8.0 mg/dL and 0.848; IL-6, 133.0 pg/mL and 0.777; and KL-6, 382.0 IU/mL and 0.707. Similarly, cut-off levels and AUCs among the biomarkers 3 days after admission were as follows: CRP: 1.4 mg/dL and 0.782; HMGB-1, 13.4 ng/mL and 0.857; d-dimer, 1.9 µg/mL and 0.772; and platelet counts, 17.2 cells/µL and 0.704. All biomarkers had AUC values > 0.700 in ROC analyses related to the start of MV. We demonstrated that the ROC analysis results were valid by implementing 5-repeated 10-fold cross-validation (Table S1).
Moreover, we analyzed the correlation among biomarkers at admission and 3 days after admission using Spearman’s rank correlation. There was a significant correlation among some biomarkers (Table S2).

4. Discussion

In the present study, we focused on determining independent biomarkers associated with the deterioration of COVID-19 among several candidates reported previously. Moreover, we focused on determining early-phase biomarkers associated with the development of critical respiratory failure requiring MV after admission.
In the present study, we clarified the role of biomarkers that are elevated both immediately and later after tissue damage, such as HMGB-1, a late inflammatory mediator, in COVID-19 patients. HMGB-1 is one of the damage-associated molecular pattern molecules (DAMPs) and endogenous “alarmin” molecules released from dead or damaged cells [24,25,26]. Excessive amounts of extracellular HMGB-1 cause the release of proinflammatory cytokines, including tumor necrosis factor-α, IL-1, IL-18, and IL-6, via the receptor for advanced glycation end products (RAGE) and Toll-like receptor 4. Aberrantly expressed extracellular HMGB-1 is considered to act as a cytokine [27,28]. HMGB-1 is associated with sepsis, malignancy, and immune disease, including ALI/ARDS [29]. In a clinical study, mortality in patients with bacterial pneumonia complicated by ALI/ARDS was strongly predicted by initial appropriate antibiotic use and plasma HMGB-1 levels [30]. HMGB-1 was reported to predict the development of acute exacerbation (AE) appearing pathologically as diffuse alveolar damage, and ALI/ARDS and mortality after AE onset, in idiopathic interstitial pneumonia patients [31,32,33]. Moreover, Chen et al. reported that serum HMGB-1 concentrations are elevated in severe COVID-19 patients, and exogenous HMGB-1 induces the expression of the SARS-CoV-2 entry receptor for angiotensin-converting enzyme-2 in alveolar epithelial cells in a RAGE-dependent manner [8]. Chen et al. also reported that elevated serum levels of S100A8/A9 and HMGB-1 at admission were correlated with high ICU admission rates and mortality in COVID-19 patients [34]. HMGB-1 is a late inflammatory mediator because it first appears in the extracellular environment 8–12 h after the initial macrophage response to proinflammatory stimuli [35]. In this study, the fact that HMGB-1 levels were associated with time-to-MV in serum collected 3 days after admission but not at admission is consistent with this feature. Extracellular HMGB-1 regulates delayed innate immune responses and provides a biomarker for predicting the development of ARDS due to COVID-19.
KL-6, a human MUC1 mucin protein, is a potential biomarker for diagnosing and predicting the severity and mortality of interstitial lung disease [36,37,38,39]. KL-6 concentrations are elevated by injury and/or remodeling of type II pneumocytes and could be detected in serum, pulmonary epithelial lining fluid, and/or bronchoalveolar lavage fluid [33,34,35]. Serum KL-6 concentrations are also elevated in patients with ALI/ARDS compared with controls and in non-survivors compared with survivors [40,41,42]. ARDS is characterized by the influx of protein-rich edema fluid into air spaces because of an increased permeability of the alveolar–capillary barrier. Moreover, pathologically, ARDS patients show fibroblast proliferation and type II alveolar epithelial cell remodeling following acute lung tissue damage [39,43]. Serum KL-6 levels are considered a biomarker for predicting critical respiratory failure in COVID-19 patients by detecting the early phase of ARDS. In some previous reports, the serum KL-6 concentration at admission was higher in severe COVID-19 cases compared with non-severe cases, and the optimal cut-off values were 278.3 to 642.3 U/mL for identifying severe cases [44,45,46,47,48]. Moreover, d’Alessandro et al. reported that KL-6 was higher in COVID-19 patients with fibrotic lung alterations than in the non-fibrotic group [49]. In contrast, Nishida et al. previously reported that elevated KL-6 and surfactant protein D were not significant in pandemic influenza A infections associated with chest radiographic abnormalities. The authors stated that pandemic influenza A infection was likely mainly caused by obstruction of peripheral bronchi, but alveolar involvement was estimated to be minimal [50]. This fact may reflect the difference in the pathophysiology of lower respiratory infection caused by COVID-19 compared with other viruses.
In the present study, CRP was the only biomarker associated with time-to-MV both at admission and 3 days after admission. In contrast, IL-6 was significantly associated with time-to-MV only at admission. Some studies have reported that IL-6 is an independent biomarker associated with outcomes in COVID-19 patients [9,10]. Popadic et al. reported that IL-6, serum albumin, and d-dimer levels were independent predictors of mortality in patients with moderate to severe ALI/ARDS requiring high-flow oxygen therapy [11]. The present study and previous studies found that serum IL-6 and CRP levels were associated with the need for MV [12]. Hyperinflammation and hypoxia-induced injury caused by SARS-CoV-2 infection induced endothelial cell dysfunction and increased thrombosis and d-dimer [13]. Previous studies showed that d-dimer levels were associated with severity and outcomes in COVID-19 patients [5,11,14,15,16]. Zheng et al. reported that thrombocytopenia, neutrophilia, and lymphocytopenia were independent biomarkers associated with outcomes in COVID-19 patients in a retrospective study, as shown in the present study [51].
The present study has limitations. First, the sample size was small for a comprehensive evaluation of many biomarkers, mainly because the study was conducted at only one center. Second, the study design was retrospective. Third, although the present study focused on determining biomarkers associated with the development of critical respiratory failure by measuring biomarker values early after admission, changes in these values may be associated with the efficacy of therapy and disease progression in COVID-19 patients. Moreover, complications such as diabetes mellitus were able to influence the outcome of study subjects. We plan to analyze the changes in biomarker levels over time, and complications, in a prospective study with larger populations with COVID-19. In addition, the accumulation of studies similar to the present study may enable the prediction of outcomes for this disease. Fourth, biomarkers measured at onset more accurately reflect the clinical course of COVID-19. The lead time bias caused by measuring biomarkers early after admission but not at onset in the present study could not be corrected with a retrospective study design.

5. Conclusions

In the present study, we found that increased CRP, IL-6, KL-6, HMGB-1, and d-dimer levels and decreased platelet counts early after admission were associated with the start of MV due to COVID-19. The development of biomarkers that support medical decision making in COVID-19 patients, including whether to initiate MV, is important. Further confirmation is needed to establish the clinical usefulness of these biomarkers because the AUCs were not excellent in the present study. The take-home message of the present study is as follows: “biomarkers that reflect inflammation, lung fibrosis, and coagulation measured at the early phase of the disease were associated with the development of critical respiratory failure due to COVID-19”.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/diagnostics12020339/s1, Table S1: Validation analyses of the ROC analyses, Table S2: Correlation among biomarkers.

Author Contributions

Conceptualization, H.Y., M.O., Y.N., S.Y., Y.Z., N.H., T.H. and S.M.; methodology, H.Y., M.O., Y.N., S.Y., Y.Z., N.H., A.K., T.H. and S.M.; validation, H.Y., M.O., Y.N., S.Y., Y.Z., N.H. and A.K.; formal analysis, H.Y., M.O., Y.N., S.Y., Y.Z., N.H. and A.K.; investigation, H.Y., M.O., Y.N., T.N., C.Y., T.T., F.W., N.S., Y.A. and Y.F.; resources, H.Y., M.O., Y.N., T.N., C.Y., T.T., F.W., N.S., Y.A. and Y.F.; data curation, H.Y., M.O. and N.S.; writing—original draft preparation, H.Y.; writing—review and editing, all authors; supervision, M.O., Y.N., Y.Z., T.H. and S.M.; project administration, M.O., Y.N., Y.Z., N.H., T.H. and S.M.; funding acquisition, M.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted according to the guidelines of the Declaration of Helsinki 2013. Informed consent was obtained in the form of an opt-out methodology for analyses of biomarkers measured in clinical practice and measurement and analysis of non-commercialized biomarkers in residual serum. All procedures in the present study were approved by the Institutional Review Board of the National Hospital Organization Kyushu Medical Center (approval number 20C059; 24 June 2020).

Informed Consent Statement

Informed consent was obtained in the form of an opt-out methodology between the date of approval and 31 July 2021.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical considerations.

Acknowledgments

We thank Sayoko Ishihara, Masatoshi Shimo, and the medical staff of the Department of Infectious Disease. We also thank Hiroaki Takeoka, Yoshiko Naitou-Nishida, Satoshi Sakamoto, and the medical staff of the Department of Respirology at the National Hospital Organization Kyushu Medical Center, who participated in the patients’ therapy in this study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [Green Version]
  2. Rabi, F.A.; Al Zoubi, M.S.; Kasasbeh, G.A.; Salameh, D.M.; Al-Nasser, A.D. SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens 2020, 9, 231. [Google Scholar] [CrossRef]
  3. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30, 269–271. [Google Scholar] [CrossRef]
  4. Hasan, S.S.; Capstick, T.; Ahmed, R.; Kow, C.S.; Mazhar, F.; Merchant, H.A.; Zaidi, S.T.R. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: A systematic review and meta-analysis. Expert Rev. Respir. Med. 2020, 14, 1149–1163. [Google Scholar] [CrossRef]
  5. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020, 180, 934–943. [Google Scholar] [CrossRef] [Green Version]
  6. Prompetchara, E.; Ketloy, C.; Palaga, T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol. 2020, 38, 1–9. [Google Scholar] [CrossRef]
  7. Słomka, A.; Kowalewski, M.; Żekanowska, E. Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations. Pathogens 2020, 9, 493. [Google Scholar] [CrossRef]
  8. Chen, R.; Huang, Y.; Quan, J.; Liu, J.; Wang, H.; Billiar, T.R.; Lotze, M.T.; Zeh, H.J.; Kang, R.; Tang, D. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon 2020, 6, e05672. [Google Scholar] [CrossRef]
  9. Del Valle, D.M.; Kim-Schulze, S.; Huang, H.-H.; Beckmann, N.D.; Nirenberg, S.; Wang, B.; Lavin, Y.; Swartz, T.H.; Madduri, D.; Stock, A.; et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020, 26, 1636–1643. [Google Scholar] [CrossRef]
  10. Laguna-Goya, R.; Utrero-Rico, A.; Talayero, P.; Lasa-Lazaro, M.; Ramirez-Fernandez, A.; Naranjo, L.; Segura-Tudela, A.; Cabrera-Marante, O.; de Frias, E.R.; Garcia-Garcia, R.; et al. IL-6–based mortality risk model for hospitalized patients with COVID-19. J. Allergy Clin. Immunol. 2020, 146, 799–807.e9. [Google Scholar] [CrossRef]
  11. Popadic, V.; Klasnja, S.; Milic, N.; Rajovic, N.; Aleksic, A.; Milenkovic, M.; Crnokrak, B.; Balint, B.; Todorovic-Balint, M.; Mrda, D.; et al. Predictors of Mortality in Critically Ill COVID-19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy. Oxidative Med. Cell. Longev. 2021, 2021, 6648199. [Google Scholar] [CrossRef]
  12. Herold, T.; Jurinovic, V.; Arnreich, C.; Lipworth, B.J.; Hellmuth, J.C.; von Bergwelt-Baildon, M.; Klein, M.; Weinberger, T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020, 146, 128–136.e4. [Google Scholar] [CrossRef]
  13. Zhang, L.; Yan, X.; Fan, Q.; Liu, H.; Liu, X.; Liu, Z.; Zhang, Z. d-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J. Thromb. Haemost. 2020, 18, 1324–1329. [Google Scholar] [CrossRef]
  14. Ayanian, S.; Reyes, J.; Lynn, L.; Teufel, K. The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cohort. Biomark. Med. 2020, 14, 1091–1097. [Google Scholar] [CrossRef]
  15. Li, Y.; Deng, Y.; Ye, L.; Sun, H.; Du, S.; Huang, H.; Zeng, F.; Chen, X.; Deng, G. Clinical Significance of Plasma d-Dimer in COVID-19 Mortality. Front. Med. 2021, 8, 638097. [Google Scholar] [CrossRef]
  16. Zhan, H.; Chen, H.; Liu, C.; Cheng, L.; Yan, S.; Li, H.; Li, Y. Diagnostic Value of d-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. Clin. Appl. Thromb. Hemost. 2021, 27, 10760296211010976. [Google Scholar] [CrossRef]
  17. Knight, S.R.; Ho, A.; Pius, R.; Buchan, I.; Carson, G.; Drake, T.M.; Dunning, J.; Fairfield, C.J.; Gamble, C.; Green, C.A.; et al. Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Development and validation of the 4C Mortality Score. BMJ 2020, 370, m3339. [Google Scholar] [CrossRef]
  18. Liang, W.; Liang, H.; Ou, L.; Chen, B.; Chen, A.; Li, C.; Li, Y.; Guan, W.; Sang, L.; Lu, J.; et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern. Med. 2020, 180, 1081–1089. [Google Scholar] [CrossRef]
  19. National Institutes of Health Website. Available online: https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/ (accessed on 13 May 2020).
  20. Pisano, A.; Yavorovskiy, A.; Verniero, L.; Landoni, G. Indications for Tracheal Intubation in Patients With Coronavirus Disease 2019 (COVID-19). J. Cardiothorac. Vasc. Anesth. 2021, 35, 1276–1280. [Google Scholar] [CrossRef]
  21. Hoshino, T.; Okamoto, M.; Sakazaki, Y.; Kato, S.; Young, H.A.; Aizawa, H. Role of Proinflammatory Cytokines IL-18 and IL-1β in Bleomycin-Induced Lung Injury in Humans and Mice. Am. J. Respir. Cell Mol. Biol. 2009, 41, 661–670. [Google Scholar] [CrossRef]
  22. Stilund, M.; Gjelstrup, M.C.; Petersen, T.; Møller, H.J.; Rasmussen, P.V.; Christensen, T. Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel. PLoS ONE 2015, 10, e0119681. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Tajiri, M.; Okamoto, M.; Fujimoto, K.; Johkoh, T.; Ono, J.; Tominaga, M.; Azuma, K.; Kawayama, T.; Ohta, S.; Izuhara, K.; et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir. Investig. 2015, 53, 73–81. [Google Scholar] [CrossRef] [PubMed]
  24. Andersson, U.; Tracey, K.J. HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection. Annu. Rev. Immunol. 2011, 29, 139–162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Kang, R.; Chen, R.; Zhang, Q.; Hou, W.; Wu, S.; Cao, L.; Huang, J.; Yu, Y.; Fan, X.-G.; Yan, Z.; et al. HMGB1 in health and disease. Mol. Asp. Med. 2014, 40, 1–116. [Google Scholar] [CrossRef] [Green Version]
  26. Andersson, U.; Yang, H.; Harris, H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin. Immunol. 2018, 38, 40–48. [Google Scholar] [CrossRef]
  27. Park, J.S.; Svetkauskaite, D.; He, Q.; Kim, J.Y.; Strassheim, D.; Ishizaka, A.; Abraham, E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 2004, 279, 7370–7377. [Google Scholar] [CrossRef] [Green Version]
  28. Andersson, U.; Ottestad, W.; Tracey, K.J. Extracellular HMGB1: A therapeutic target in severe pulmonary inflammation including COVID-19? Mol. Med. 2020, 26, 42. [Google Scholar] [CrossRef]
  29. Qu, L.; Chen, C.; Chen, Y.; Li, Y.; Tang, F.; Huang, H.; He, W.; Zhang, R.; Shen, L. High-Mobility Group Box 1 (HMGB1) and Autophagy in Acute Lung Injury (ALI): A Review. Med. Sci. Monit. 2019, 25, 1828–1837. [Google Scholar] [CrossRef]
  30. Tseng, C.-C.; Fang, W.-F.; Leung, S.Y.; Chen, H.-C.; Chang, Y.-C.; Wang, C.-C.; Chang, H.-C.; Lin, M.-C. Impact of Serum Biomarkers and Clinical Factors on Intensive Care Unit Mortality and 6-Month Outcome in Relatively Healthy Patients with Severe Pneumonia and Acute Respiratory Distress Syndrome. Dis. Markers 2014, 2014, 804654. [Google Scholar] [CrossRef] [Green Version]
  31. Hamada, N.; Maeyama, T.; Kawaguchi, T.; Yoshimi, M.; Fukumoto, J.; Yamada, M.; Yamada, S.; Kuwano, K.; Nakanishi, Y. The Role of High Mobility Group Box1 in Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol. 2008, 39, 440–447. [Google Scholar] [CrossRef]
  32. Yamaguchi, K.; Iwamoto, H.; Sakamoto, S.; Horimasu, Y.; Masuda, T.; Miyamoto, S.; Nakashima, T.; Ohshimo, S.; Fujitaka, K.; Hamada, H.; et al. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis. Respirology 2020, 25, 275–280. [Google Scholar] [CrossRef] [PubMed]
  33. Shimizu, H.; Sakamoto, S.; Isshiki, T.; Furuya, K.; Kurosaki, A.; Homma, S. Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. PLoS ONE 2018, 13, e0196558. [Google Scholar] [CrossRef] [PubMed]
  34. Chen, L.; Long, X.; Xu, Q.; Tan, J.; Wang, G.; Cao, Y.; Wei, J.; Luo, H.; Zhu, H.; Huang, L.; et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell. Mol. Immunol. 2020, 17, 992–994. [Google Scholar] [CrossRef] [PubMed]
  35. Andersson, U.; Tracey, K.J. HMGB1 in Sepsis. Scand. J. Infect. Dis. 2003, 35, 577–584. [Google Scholar] [CrossRef]
  36. Kohno, N.; Awaya, Y.; Oyama, T.; Yamakido, M.; Akiyama, M.; Inoue, Y.; Yokoyama, A.; Hamada, H.; Fujioka, S.; Hiwada, K. KL-6, a Mucin-like Glycoprotein, in Bronchoalveolar Lavage Fluid from Patients with Interstitial Lung Disease. Am. Rev. Respir. Dis. 1993, 148, 637–642. [Google Scholar] [CrossRef]
  37. Yokoyama, A.; Kondo, K.; Nakajima, M.; Matsushima, T.; Takahashi, T.; Nishimura, M.; Bando, M.; Sugiyama, Y.; Totani, Y.; Ishizaki, T.; et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006, 11, 164–168. [Google Scholar] [CrossRef]
  38. Ishii, H.; Mukae, H.; Kadota, J.; Kaida, H.; Nagata, T.; Abe, K.; Matsukura, S.; Kohno, S. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax 2003, 58, 52–57. [Google Scholar] [CrossRef] [Green Version]
  39. Ishikawa, N.; Hattori, N.; Yokoyama, A.; Kohno, N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Investig. 2012, 50, 3–13. [Google Scholar] [CrossRef] [Green Version]
  40. Kondo, T.; Hattori, N.; Ishikawa, N.; Murai, H.; Haruta, Y.; Hirohashi, N.; Tanigawa, K.; Kohno, N. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome. Respir. Res. 2011, 12, 32. [Google Scholar] [CrossRef] [Green Version]
  41. Ishizaka, A.; Matsuda, T.; Albertine, K.H.; Koh, H.; Tasaka, S.; Hasegawa, N.; Kohno, N.; Kotani, T.; Morisaki, H.; Takeda, J.; et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286, L1088–L1094. [Google Scholar] [CrossRef]
  42. Sato, H.; Callister, M.E.J.; Mumby, S.; Quinlan, G.J.; Welsh, K.I.; Dubois, R.M.; Evans, T.W. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur. Respir. J. 2004, 23, 142–145. [Google Scholar] [CrossRef] [PubMed]
  43. Matthay, M.A.; Zemans, R.L.; Zimmerman, G.A.; Arabi, Y.M.; Beitler, J.R.; Mercat, A.; Herridge, M.; Randolph, A.G.; Calfee, C.S. Acute respiratory distress syndrome. Nat. Rev. Dis. Primers 2019, 5, 18. [Google Scholar] [CrossRef] [PubMed]
  44. d’Alessandro, M.; Cameli, P.; Refini, R.M.; Bergantini, L.; Alonzi, V.; Lanzarone, N.; Bennett, D.; Rana, G.D.; Montagnani, F.; Scolletta, S.; et al. Serum KL-6 concentrations as a novel biomarker of severe COVID-19. J. Med. Virol. 2020, 92, 2216–2220. [Google Scholar] [CrossRef] [PubMed]
  45. Awano, N.; Inomata, M.; Kuse, N.; Tone, M.; Takada, K.; Muto, Y.; Fujimoto, K.; Akagi, Y.; Mawatari, M.; Ueda, A.; et al. Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019. Respir. Investig. 2020, 58, 440–447. [Google Scholar] [CrossRef]
  46. Deng, K.; Fan, Q.; Yang, Y.; Deng, X.; He, R.; Tan, Y.; Lan, Y.; Deng, X.; Pan, Y.; Wang, Y.; et al. Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis. J. Med. Virol. 2021, 93, 2505–2512. [Google Scholar] [CrossRef] [PubMed]
  47. D’Alessandro, M.; Bergantini, L.; Cameli, P.; Curatola, G.; Remediani, L.; Sestini, P.; Bargagli, E.; Siena COVID Unit. Peripheral biomarkers’ panel for severe COVID-19 patients. J. Med. Virol. 2021, 93, 1230–1232. [Google Scholar] [CrossRef]
  48. Crisan-Dabija, R.; Covic, A.; Brinza, C.; Popa, I.V.; Burlacu, A. Involvement of KL-6 Biomarker in Interstitial Lung Disease Induced by SARS-CoV-2 Infection: A Systematic Review. Appl. Sci. 2021, 11, 3482. [Google Scholar] [CrossRef]
  49. D’Alessandro, M.; Bergantini, L.; Cameli, P.; Curatola, G.; Remediani, L.; Bennett, D.; Bianchi, F.; Perillo, F.; Volterrani, L.; Mazzei, M.A.; et al. Serial KL-6 measurements in COVID-19 patients. Intern. Emerg. Med. 2021, 16, 1541–1545. [Google Scholar] [CrossRef]
  50. Nishida, S.; Fukazawa, R.; Imai, T.; Takeda, S.; Hayakawa, J.; Takeuchi, H.; Shimizu, K.; Kawakami, Y.; Takase, M. Serum KL-6 and surfactant protein D in children with 2009 pandemic H1N1 influenza infection. Pediatr. Int. 2011, 53, 910–914. [Google Scholar] [CrossRef]
  51. Zheng, Y.; Zhang, Y.; Chi, H.; Chen, S.; Peng, M.; Luo, L.; Chen, L.; Li, J.; Shen, B.; Wang, D. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: A retrospective study. Clin. Chem. Lab. Med. 2020, 58, 1106–1115. [Google Scholar] [CrossRef]
Diagnostics 12 00339 g001 550
Figure 1. Receiver operating characteristic curves for detecting the association between biomarkers and the start of MV. The receiver operating characteristic curves for detecting the association between independent biomarkers in the Cox proportional hazards regression analysis and the start of MV are shown. (A) CRP, (B) interleukin-6, and (C) KL-6 at admission, and (D) CRP, (E) platelet counts, (F) HMGB-1, and (G) d-dimer 3 days after admission. Among the biomarkers at admission, the cut-off levels were as follows: CRP, 8.0 mg/dL; IL-6, 133.0 pg/mL; and KL-6, 382.0 IU/mL. Similarly, the cut-off levels among the biomarkers 3 days after admission were as follows: CRP: 1.4 mg/dL; HMGB-1, 13.4 ng/mL; d-dimer, 1.9 µg/mL; and platelet counts, 17.2 cells/µL. The cut-off levels for the various parameters were defined as the optimal value with the highest Youden index in the receiver operating characteristic curve analysis. COVID-19, coronavirus disease 2019; CRP: C-reactive protein; IL, interleukin; AUC, area under the curve; KL-6, Krebs von den Lungen-6; HMGB-1, high-mobility group box-1 protein; MV, mechanical ventilation. * A value of p < 0.05 was considered to represent statistical significance.
Figure 1. Receiver operating characteristic curves for detecting the association between biomarkers and the start of MV. The receiver operating characteristic curves for detecting the association between independent biomarkers in the Cox proportional hazards regression analysis and the start of MV are shown. (A) CRP, (B) interleukin-6, and (C) KL-6 at admission, and (D) CRP, (E) platelet counts, (F) HMGB-1, and (G) d-dimer 3 days after admission. Among the biomarkers at admission, the cut-off levels were as follows: CRP, 8.0 mg/dL; IL-6, 133.0 pg/mL; and KL-6, 382.0 IU/mL. Similarly, the cut-off levels among the biomarkers 3 days after admission were as follows: CRP: 1.4 mg/dL; HMGB-1, 13.4 ng/mL; d-dimer, 1.9 µg/mL; and platelet counts, 17.2 cells/µL. The cut-off levels for the various parameters were defined as the optimal value with the highest Youden index in the receiver operating characteristic curve analysis. COVID-19, coronavirus disease 2019; CRP: C-reactive protein; IL, interleukin; AUC, area under the curve; KL-6, Krebs von den Lungen-6; HMGB-1, high-mobility group box-1 protein; MV, mechanical ventilation. * A value of p < 0.05 was considered to represent statistical significance.
Diagnostics 12 00339 g001
Table
Table 1. Patient characteristics.
Table 1. Patient characteristics.
All CasesAsymptomatic or Mild at AdmissionModerate at AdmissionSevere at Admissionp Value
N135426627
Age (years)50.0 (35.0–70.0)32.5 (26.0–49.0)53.5 (39.0–72.3)67.0 (51.0–72.0)<0.00010 *
Gender, Male69 (51%)8 (19.1%)40 (60.6%)21 (77.8%)<0.00010 *
Smoker56 (47.5%)19 (48.7%)28 (46.7%)9 (47.4%)1.0
Complication
Diabetes mellitus22 (16.3%)1 (2.4%)11 (16.7%)10 (37.0%)0.014 *
Hypertension33 (24.4%)4 (9.5%)16 (24.2%)13 (48.2%)0.0014 *
Malignant disease9 (6.7%)1 (2.4%)5 (7.6%)3 (11.1%)0.39
Data at admission
Neutrophil counts (/µL)3737.0 (2664.0–5883.0)3278.2 (2303.2–4670.6)3465.5 (2556.9–5032.9)5893.0 (4012.0–8333.4)<0.0001 *
Lymphocyte counts (/µL)1360.1 (952.0–1757.5)1635.1 (1038.0–1823.8)1211.8 (922.1–1610.8)1354.5 (844.9–1925.7)0.048 *
Platelet counts (×104/µL)18.5 (15.6–24.0)20.4 (16.9–24.5)18.7 (15.4–25.5)18.0 (13.6–20.5)0.18
CRP (mg/dL)1.5 (0.22–4.7)0.14 (0.05–0.59)2.3 (1.1–4.6)6.9 (3.0–10.7)<0.00010 *
Lactate dehydrogenase (IU/L)219.0 (177.0–296.0)174.5 (156.8–201.3)220.5 (188.5–264.3)390.0 (298.0–485.0)<0.00010 *
Ferritin (ng/mL)337.0 (114.0–743.1)99.5 (33.8–136.0)371.8 (251.6–668.6)1116.4 (643.0–1698.9)<0.00010 *
Interleukin-6 (pg/mL)9.1 (2.4–20.8)1.8 (1.3–4.5)11.4 (5.8–21.2)20.4 (8.4–58.9)<0.00010 *
Interleukin-18 (pg/mL)295.0 (207.5–406.0)227.5 (175.0–310.0)290.0 (210.0–406.0)502.5 (353.5–678.8)<0.00010 *
KL-6 (IU/mL)220.5 (185.0–294.3)204.5 (168.8–264.3)224.0 (184.0–289.0)312.0 (210.0–410.0)0.0010 *
HMGB-1 (ng/mL)6.5 (4.1–9.4)7.3 (5.8–11.0)5.4 (3.2–8.8)6.6 (5.1–11.9)0.13
Soluble CD163 (ng/mL)558.5 (459.8–724.0)513.0 (435.0–694.0)529.5 (440.5–631.5)748.0 (501.0–886.0)0.1
d-dimer (µg/mL)0.50 (0.30–1.1)0.40 (0.20–0.55)0.40 (0.20–1.1)1.1 (0.60–1.7)<0.00010 *
Data at day 3 <0.00010 *
Neutrophil counts (/µL)3011.4 (2073.0–4951.0)2521.1 (1740.6–3844.9)2808.0 (2007.8–4048.9)6706.0 (3063.7–9683.2)<0.00010 *
Lymphocyte counts (/µL)1278.9 (900.6–1847.3)1818.0 (1332.4–2118.0)1171.8 (792.0–1729.0)1040.7 (599.8–1321.3)<0.00010 *
Platelet counts (×104/µL)20.5 (16.3–26.4)20.7 (17.0–26.1)19.8 (15.1–27.2)22.0 (17.6–28.3)0.70
CRP (mg/dL)1.4 (0.26–4.6)0.070 (0.050–0.32)2.1 (0.77–7.1)5.0 (1.8–9.4)<0.00010 *
Lactate dehydrogenase (IU/L)214.0 (170.0–306.8)164.0 (138.0–195.0)226.0 (181.0–275.0)371.0 (310.5–491.8)<0.00010 *
Ferritin (ng/mL)467.8 (142.3–978.5)85.1 (21.0–132.2)469.8 (228.0–964.5)869.2 (666.6–1681.8)<0.00010 *
Interleukin-6 (pg/mL)7.7 (2.4–23.1)1.8 (1.2–2.7)10.0 (4.2–20.0)20.2 (5.8–37.9)<0.00010 *
HMGB-1 (ng/mL)8.5 (5.1–14.7)6.3 (4.3–9.5)7.0 (5.0–11.0)15.2 (8.7–21.4)0.00010 *
Soluble CD163 (ng/mL)617.0 (459.5–886.0)463.0 (342.8–630.5)597.0 (459.3–808.8)878.0 (650.5–1000.0)<0.00010 *
d-dimer (µg/mL)0.60 (0.40–1.3)0.40 (0.20–0.60)0.60 (0.40–1.4)1.0 (0.50–4.8)0.0016 *
CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; HMGB-1, high-mobility group box-1 protein. * A value of p < 0.05 was considered to represent statistical significance.
Table
Table 2. Patient outcomes.
Table 2. Patient outcomes.
All Cases
at Admission		Asymptomatic or Mild at AdmissionModerate
at Admission		Severe
at Admission		p Value
N135426627
Started MV or died11 (8.1%)06 (9.1%)5 (18.5%)0.015 *
Started MV and survived6 (4.4%)04 (6.1%)2 (7.4%)0.21
Started MV and died4 (3.0%)01 (1.5%)3 (11.1%)0.034 *
Survived without MV124 (91.9%)42 (100%)60 (90.9%)22 (81.5%)0.015 *
Died without MV1 (0.74%)01 (1.5%)01
Duration from admission to start of MV2.0 (0–8.0)-8.0 (1.5–8.5)0 (0–2.5)0.084
MV, mechanical ventilation. * A value of p < 0.05 was considered to represent statistical significance.
Table
Table 3. Comparison between patients who started MV and others.
Table 3. Comparison between patients who started MV and others.
Started MV
YesNop Value
N10 (7.4%)125 (92.6%)
Data at admission
Neutrophil counts (/µL)6104.1 (4162.6–8076.9)3570.0 (2642.4–5302.8)0.017 *
Lymphocyte counts (/µL)1007.0 (749.0–1384.2)1419.6 (958.0–1765.1)0.084 *
Platelet counts (×104/µL)14.4 (12.3–25.9)18.9 (16.2–23.9)0.070
CRP (mg/dL)9.2 (3.7–17.9)1.4 (0.19–4.2)0.00030 *
Lactate dehydrogenase (IU/L)381.0 (229.8–525.0)213.0 (174.5–277.5)0.0017 *
Ferritin (ng/mL)1243.3 (627.1–2095.0)294.9 (102.5–635.6)0.00020 *
Interleukin-6 (pg/mL)315.5 (215.8–1027.0)213.0 (183.0–285.0)0.052
Interleukin-18 (pg/mL)5.0 (3.6–19.1)6.6 (4.1–9.4)0.67
KL-6 (IU/mL)827.5 (541.0–971.5)539.5 (446.8–695.5)0.094
HMGB-1 (ng/mL)7.0 (4.7–11.2)6.3 (4.0–9.5)0.67
Soluble CD163 (ng/mL)717.0 (465.0–886.0)541.0 (435.0–696.0)0.19
d-dimer (µg/mL)1.9 (0.60–3.9)0.40 (0.20–0.95)0.00070 *
Data at day 3
Neutrophil counts (/µL)6532.0 (3443.0–9246.2)2953.0 (2044.5–4524.6)0.012 *
Lymphocyte counts (/µL)568.3 (440.6–885.5)1344.0 (983.5–1866.4)0.00070 *
Platelet counts (×104/µL)15.3 (13.3–21.8)20.8 (16.9–26.9)0.033 *
CRP (mg/dL)6.0 (2.0–25.2)1.2 (0.19–4.0)0.0031 *
Lactate dehydrogenase (IU/L)326.5 (292.8–446.3)207.0 (165.8–284.3)0.0020 *
Ferritin (ng/mL)1104.4 (640.7–2199.9)420.5 (126.1–865.9)0.0022 *
Interleukin-6 (pg/mL)56.4 (27.9–164.0)6.7 (2.3–18.6)0.0011 *
HMGB-1 (ng/mL)16.4 (14.8–32.9)7.9 (5.0–11.5)0.0037 *
Soluble CD163 (ng/mL)766.0 (502.5–1000.0)610.5 (459.3–825.8)0.32
d-dimer (µg/mL)4.8 (0.55–60.1)0.50 (0.30–1.0)0.0071 *
MV, mechanical ventilation; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; HMGB-1, high-mobility group box-1 protein. * A value of p < 0.05 was considered to represent statistical significance.
Table
Table 4. Univariate analysis by Cox proportional hazards regression analysis for biomarkers associated with time-to-MV.
Table 4. Univariate analysis by Cox proportional hazards regression analysis for biomarkers associated with time-to-MV.
A. Analysis of biomarkers at admission
RR95%CIpValue
Neutrophil (µL)54.73.4–489.50.0077 *
Lymphocyte (µL)0.0220.00013–1.60.086
Platelet (×104/µL)0.140.0014–7.50.35
CRP (mg/dL)51.48.7–318.4<0.00010 *
Lactate dehydrogenase (IU/L)188.514.6–2152.10.00020 *
Ferritin (ng/mL)108.710.3–845.60.00070 *
Interleukin-6 (pg/mL)26.63.2–139.20.0053 *
Interleukin-18 (pg/mL)7.20.057–106.50.35
KL-6 (IU/mL)89.48.6–654.10.0012 *
HMGB-1 (ng/mL)1.90.0015–55.90.81
Soluble CD163 (ng/mL)10.80.34–340.90.17
d-dimer (µg/mL)91.69.5–697.50.00070 *
B. Analysis of biomarkers at 3 days after admission
RR95%CIpValue
Neutrophil (µL)41.12.9–344.90.0090 *
Lymphocyte (µL)0.0380.00057–0.0018 §0.33
Platelet (×104/µL)0.0130.00012–0.870.043 *
CRP (mg/dL)53.27.6–338.60.00020 *
Lactate dehydrogenase (IU/L)25.8 2.5–180.00.0087 *
Ferritin (ng/mL)20.52.0–117.00.015 *
Interleukin-6 (pg/mL)45.14.7–293.20.0031 *
HMGB-1 (ng/mL)2219.833.0–600,284.40.00050 *
Soluble CD163 (ng/mL)3.7 0.29–54.60.31
d-dimer (µg/mL)123.310.7–1659.50.00070 *
§ parameter estimates. MV, mechanical ventilation; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; HMGB-1, high-mobility group box-1 protein; RR, relative risk; 95% CI, 95% confidence interval. * A value of p < 0.05 was considered to represent statistical significance.
Table
Table 5. Multivariate analysis by Cox proportional hazards regression analysis for biomarkers associated with time-to-MV.
Table 5. Multivariate analysis by Cox proportional hazards regression analysis for biomarkers associated with time-to-MV.
A. Analysis of biomarkers at admission
RR95%CIpValue
CRP (mg/dL)33.13.2–372.60.0028 *
Interleukin-6 (pg/mL)14.50.67–142.70.041 *
KL-6 (IU/mL)64.73.6–804.40.0013 *
B. Analysis of biomarkers at 3 days after admission
RR95%CIpValue
Platelet (×104/µL)−0.37 §−0.72–−0.14 §0.00060 *
CRP (mg/dL)−0.33 §−0.96–−0.044 §0.021 *
HMGB-1 (ng/mL)0.22 §0.054–0.46 §0.011 *
d-dimer (µg/mL)0.93 §0.083–2.1 §0.00037 *
§ parameter estimates; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; HMGB-1, high-mobility group box-1 protein; RR, relative risk; 95% CI, 95% confidence interval. * A value of p < 0.05 was considered to represent statistical significance.
Table
Table 6. Receiver operating characteristic curve analysis for detecting the association between biomarkers and the start of MV.
Table 6. Receiver operating characteristic curve analysis for detecting the association between biomarkers and the start of MV.
A. Analysis of biomarkers at admission
Cut-OffAUCSensitivitySpecificitypValue
Neutrophil (/µL)4672.6 0.72780.0%69.6%0.0089 *
Lymphocyte (/µL)1333.5 0.66580.0%54,4%0.083
Platelet (×104/µL)14.90.67270.0%84.8%0.33
CRP (mg/dL)8.0 0.84870.0%92.0%<0.0001 *
Lactate dehydrogenase (IU/L)372.0 0.79860.0%89.6%0.0003 *
Ferritin (ng/mL)706.50.855 80.0%78.3%0.0004 *
Interleukin-6 (pg/mL)133.0 0.777 50.0%97.5%0.0038 *
Interleukin-18 (pg/mL)281.0 0.655 85.7%50.0%0.35
KL-6 (IU/mL)382.0 0.707 50.0%96.4%0.0004 *
HMGB-1 (ng/mL)7.0 0.547 57.1%39.8%0.82
Soluble CD163 (ng/mL)675.0 0.648 71.4%72.8%0.19
d-dimer (µg/mL)1.2 0.789 70.0%81.3%0.0006 *
B. Analysis of biomarkers at 3 days after admission
Cut-OffAUCSensitivitySpecificitypValue
Neutrophil (µL)5765.50.752 66.7%83.0%0.011 *
Lymphocyte (µL)790.0 0.826 80.0%85.8%0.35
Platelet (×104/µL)17.20.704 70.0%72.8%0.036 *
CRP (mg/dL)1.4 0.782 90.0%54.4%0.0004 *
Lactate dehydrogenase (IU/L)308.0 0.795 80.0%79.2%0.0078 *
Ferritin (ng/mL)434.20.798 100.0%50.6%0.0092 *
Interleukin-6 (pg/mL)33.80.899 83.3%91.9%0.0004 *
HMGB-1 (ng/mL)13.40.857 100.0%77.4%0.0024 *
Soluble CD163 (ng/mL)712.0 0.621 66.7%66.7%0.32
d-dimer (µg/mL)1.9 0.772 66.7%87.2%<0.0001 *
AUC, area under the curve; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; HMGB-1, high-mobility group box-1 protein; RR, relative risk; 95% CI, 95% confidence interval. * A value of p < 0.05 was considered to represent statistical significance.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Yamada, H.; Okamoto, M.; Nagasaki, Y.; Yoshio, S.; Nouno, T.; Yano, C.; Tanaka, T.; Watanabe, F.; Shibata, N.; Arimizu, Y.; et al. Analysis of Early Biomarkers Associated with the Development of Critical Respiratory Failure in Coronavirus Disease 2019 (COVID-19). Diagnostics 2022, 12, 339. https://doi.org/10.3390/diagnostics12020339

AMA Style

Yamada H, Okamoto M, Nagasaki Y, Yoshio S, Nouno T, Yano C, Tanaka T, Watanabe F, Shibata N, Arimizu Y, et al. Analysis of Early Biomarkers Associated with the Development of Critical Respiratory Failure in Coronavirus Disease 2019 (COVID-19). Diagnostics. 2022; 12(2):339. https://doi.org/10.3390/diagnostics12020339

Chicago/Turabian Style

Yamada, Hiroyoshi, Masaki Okamoto, Yoji Nagasaki, Suzuyo Yoshio, Takashi Nouno, Chiyo Yano, Tomohiro Tanaka, Fumi Watanabe, Natsuko Shibata, Yoko Arimizu, and et al. 2022. "Analysis of Early Biomarkers Associated with the Development of Critical Respiratory Failure in Coronavirus Disease 2019 (COVID-19)" Diagnostics 12, no. 2: 339. https://doi.org/10.3390/diagnostics12020339

APA Style

Yamada, H., Okamoto, M., Nagasaki, Y., Yoshio, S., Nouno, T., Yano, C., Tanaka, T., Watanabe, F., Shibata, N., Arimizu, Y., Fukamachi, Y., Zaizen, Y., Hamada, N., Kawaguchi, A., Hoshino, T., & Morita, S. (2022). Analysis of Early Biomarkers Associated with the Development of Critical Respiratory Failure in Coronavirus Disease 2019 (COVID-19). Diagnostics, 12(2), 339. https://doi.org/10.3390/diagnostics12020339

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop